Skip to main content

Advertisement

SpringerLink
Log in

Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Human epidermal growth factor receptor-2 (HER2/erbB-2) is a member of a family of four transmembrane receptor tyrosine kinases that regulate cell growth, survival and differentiation via multiple signal transduction pathways. Amplification of the HER2 gene occurs in 20–25% of human breast cancers. This amplification event is an independent adverse prognostic factor as well as a predictive factor for increased response to doxorubicin-based combination chemotherapy, response to trastuzumab and decreased response to hormonal therapy. Methods for detecting protein overexpression or gene amplification in clinical tumor specimens include immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) techniques, with the latter considered by some to be more accurate. Trastuzumab (Herceptin) is a recombinant humanized monoclonal antibody which targets an epitope in the extracellular domain of the HER2 protein. Preclinical models demonstrated that this antibody has significant anti-tumor activity as a single agent and has synergy with certain chemotherapeutic drugs. Phase II and III clinical trials performed in women with metastatic breast cancer that overexpress HER2 have shown that trastuzumab has clinical activity when used as first-, second- or third-line monotherapy, and improves survival when used as first-line therapy in combination with chemotherapy. Newer combinations with numerous chemotherapeutic drugs have also shown significant clinical activity in phase II studies. In all of these trials, trastuzumab was generally well-tolerated, but cardiac toxicity (particularly when the antibody was combined with anthracyclines) was an unexpected adverse effect. Although trastuzumab is currently usually administered on a weekly intravenous schedule, evidence suggests that a triple dose of the drug given once every three weeks has a pharmacokinetic profile expected to be equally efficacious. Neither the optimal schedule nor the optimal duration of trastuzumab therapy has yet been clearly defined in controlled clinical trials. Current clinical investigations of trastuzumab include its use in both the adjuvant and neoadjuvant settings as well as in combination with other chemotherapy drugs or new biologic targeted agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon D: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18: 3651–3664, 2000

    PubMed  Google Scholar 

  2. Press MF, Sauter G, Bernstein L, Zhou J, Li B, Mirlacher M, Villalobos I, Guzman R, Riva A, Nabholtz J-M, Slamon DJ: Comparison of HER-2/neu status determined by fluorescence in situ hybridization (FISH) in the BCIRG central laboratories with HER-2/neu status determined by immunohistochemistry or FISH in outside laboratories [abstract]. Breast Cancer Res Treat 76(Suppl 1): S69, 2002 (Abstract 238)

  3. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ: Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89: 10578–10582, 1992

    PubMed  Google Scholar 

  4. Chazin VR, Kaleko M, Miller AD, Slamon DJ: Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 7: 1859–1866, 1992

    PubMed  Google Scholar 

  5. Muller WJ, Ho J, Siegel PM: Oncogenic activation of Neu/ErbB-2 in a transgenic mouse model for breast cancer. Biochem Soc Symp 63: 149–157, 1998

    PubMed  Google Scholar 

  6. Andrechek ER, Hardy WR, Siegel PM, Rudnicki MA, Cardiff RD, Muller WJ: Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc Natl Acad Sci USA 97: 3444–3449, 2000

    Article  PubMed  Google Scholar 

  7. Weinstein EJ, Kitsberg DI, Leder P: A mouse model for breast cancer induced by amplification and overexpression of the neu promoter and transgene. Mol Med 6: 4–16, 2000

    PubMed  Google Scholar 

  8. Carter P, Presta L, Gorman CM, Ridgway JB, Hennder D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM: Humanization of the anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285–4289, 1992

    PubMed  Google Scholar 

  9. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792, 2001

    Article  PubMed  Google Scholar 

  10. Extra JM, Cognetti F, Chan S, Maraninchi D, Snyder R, Mauriac L, Anton A, Mefti F, Grimes D, Mayne K, Meyer-Wenger A, Marty M: First-line trastuzumab (Herceptin) plus docetaxel versus docetaxel alone in women with HER2-positive metastatic breast cancer (MBC): results from a randomized phase II trial (M77001) [abstract]. Breast Cancer Res Treat 82 (Suppl 1): S47–S48, 2003 (Abstract 217)

  11. Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, Ullrich A, Schlessinger J, Waterfield MD: Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307: 521–527, 1984

    Article  PubMed  Google Scholar 

  12. Shih C, Padhy LC, Murray M, Weinberg RA: Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 290: 261–264, 1981

    Article  PubMed  Google Scholar 

  13. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA: The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312: 513–516, 1984

    Article  PubMed  Google Scholar 

  14. Sharpe S, Barber KR, Grant CW: Val (659) ‡ Glu mutation within the transmembrane domain of ErbB-2: effects measured by (2)H NMR in fluid phospholipid bilayers. Biochemistry 39: 6572–6580, 2000

    Article  PubMed  Google Scholar 

  15. Hung MC, Yan DH, Zhao XY: Amplification of the proto-neu oncogene facilitates oncogenic activation by a single point mutation. Proc Natl Acad Sci USA 86: 2545–2548, 1989

    PubMed  Google Scholar 

  16. Bargmann CI, Weinberg RA: Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. EMBO J 7: 2043–2052, 1988

    PubMed  Google Scholar 

  17. Bargmann CI, Hung MC, Weinberg RA: Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45: 649–657, 1986

    Article  PubMed  Google Scholar 

  18. Coussens L, Yang-Feng TL, Liao Y-C, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, Levinson A, Ullrich A: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromsomal location with neu oncogene. Science 230: 1132–1139, 1985

    PubMed  Google Scholar 

  19. Semba K, Kamata N, Toyoshima K, Yamamoto T: A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 82: 6497–6501, 1985

    PubMed  Google Scholar 

  20. King CR, Kraus MH, Aaronson SA: Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229: 974–976, 1985

    PubMed  Google Scholar 

  21. Yarden Y: Biology of HER2 and its importance in breast cancer. Oncology 61 (Suppl 2): 1–13, 2001

  22. Baulida J, Kraus MH, Alimandi M, DiFiore PP, Carpenter G: All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 271: 5251–5257, 1996

    Article  PubMed  Google Scholar 

  23. Yarden Y, Sliwkowski M: Untangling the ErbB signaling network. Nat Reviews 2: 127–137, 2001

    Article  Google Scholar 

  24. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712, 1989

    PubMed  Google Scholar 

  25. Manavi M, Bauer M, Baghestanian M, Berger A, Kucera E, Pischinger K, Battistutti W, Czerwenka K: Oncogenic potential of c-erbB-2 and its association with c-K-ras in premalignant and malignant lesions of the human uterine endometrium. Tumour Biol 22: 299–309, 2001

    Article  PubMed  Google Scholar 

  26. Rolitsky CD, Theil KS, McGaughy VR, Copeland LJ, Niemann TH: HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol 18: 138–143, 1999

    PubMed  Google Scholar 

  27. Skalova A, Starek, Kucerova V, Szepe P, Plank L: Salivary duct carcinoma – a highly aggressive salivary gland tumor with HER2/neu oncoprotein overexpression. Pathol Res Pract 197: 632–636, 2001

    Google Scholar 

  28. Yokota J, Yamamoto T, Miyajima N, Toyoshima K, Nomura N, Sakamoto H, Yoshida T, Terada M, Sugimura T: Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often acompanied by amplification of the v-erbA homologue. Oncogene 2: 283–287, 1988

    PubMed  Google Scholar 

  29. Miyamoto H, Kubota Y, Noguchi S, Takase K, Matsuzaki J, Moriyama M, Takebayashi S, Kitamura H, Hosaka M: C-erbB-2 gene amplification as a prognostic marker in human bladder cancer. Urology 55: 679–683, 2000

    Article  PubMed  Google Scholar 

  30. Safran H, Steinhoff M, Mangray S, Rathore R, King TC, Chai L, Berzein K, Moore T, Iannitti D, Reiss P, Pasquariello T, Akerman P, Quirk D, Mass R, Goldstein L, Tantravahi U: Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol 24: 496–499, 2001

    Article  PubMed  Google Scholar 

  31. Pauletti G, Godolphin W, Press MF, Slamon DJ: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13: 63–72, 1996

    PubMed  Google Scholar 

  32. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ: The effect of the HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cells. Oncogene 15: 537–547, 1997

    Article  PubMed  Google Scholar 

  33. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain R: Herceptin acts as an anti-angiogenic cocktail. Nature 416: 279–280, 2002

    Article  Google Scholar 

  34. Feuerer M, Rocha M, Bai L, Umansky V, Solomayer E-F, Bastert G, Diel IJ, Schirrmacher V: Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients. Int J Cancer 92: 96–105, 2001

    Article  PubMed  Google Scholar 

  35. Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmuller G, Pantel K: Erb B2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 61: 1890–1895, 2001.

    PubMed  Google Scholar 

  36. Menard S, Fortis S, Castiglioni F, Agresti R, Balsari A: HER2 as a prognostic factor in breast cancer. Oncology 61(Suppl 2): 67–72, 2001

    Article  PubMed  Google Scholar 

  37. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95: 142–153, 2003

    PubMed  Google Scholar 

  38. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182, 1987

    PubMed  Google Scholar 

  39. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10: 1049–1056, 1992

    PubMed  Google Scholar 

  40. Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, Della Porta G, Menard S, Pierotti MA, Testori A: Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 19: 44–49, 1991

    Google Scholar 

  41. Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL, Altman DG: c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63: 434–438, 1991

    PubMed  Google Scholar 

  42. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 11: 1936–1942, 1993

    Google Scholar 

  43. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Nagger A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ: Her-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15: 2894–2904, 1997

    PubMed  Google Scholar 

  44. Press M, Pike M, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R: HER-2/neu expression in node-negative breast cancers: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53: 4960–4070, 1993

    PubMed  Google Scholar 

  45. Press MF, Slamon DJ, Flom KJ, Park J, Zhou J-Y, Bernstein L: Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20: 3095–3105, 2002

    PubMed  Google Scholar 

  46. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D’Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19: 2587–2595, 2001

    PubMed  Google Scholar 

  47. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, Brown A, Yothers G, Anderson S, Smith R, Wickerham DL, Wolmark N: Real-world performance of HER2 testing—National Surgical Adjuvant Breast and Bowel Project Experience. J Natl Cancer Institute 94: 852–854, 2002

    Google Scholar 

  48. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, Flynn PJ, Ingle JN, Visscher D, Jenkins RB: HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial [abstract]. Proc Am Soc Oncol 23: 18, 2004 (Abstract 567)

    Google Scholar 

  49. Hung MC, Lau Y-K: Basic science of HER2/neu: a review. Semin Oncol 26: 51–59, 1999

    Google Scholar 

  50. Zheng EF, Kuduk SD, Chiosis G, Munster PN, Sepp-Lorenzino L, Denishefsky SJ, Rosen N: Identification of a geldanamycin dimer that induces selective degradation of HER-family tyrosine kinases. Cancer Res 60: 2090–2094, 2000

    PubMed  Google Scholar 

  51. Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A: Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 50: 1550–1558, 1990

    PubMed  Google Scholar 

  52. Lupu R, Colomer R, Zugmaier G, Sarup J, Shepard M, Slamon D, Lippman ME: Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. Science 249: 1552–1555, 1990

    PubMed  Google Scholar 

  53. Sarup JC, Johnson RM, King KL, Fendly BM, Lipari MT, Napier MA, Ullrich A, Shepard HM: Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul 1: 72–82, 1991

    PubMed  Google Scholar 

  54. Pegram MD, Pietras R, Slamon DJ: Monoclonal antibody to HER-2/neu gene product potentiates cytotoxicity of carboplatin and doxorubicin in human breast tumor cells (abstract). Proc Am Assoc Cancer Res 33: 442, 1992 (Abstract 2639)

  55. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9: 1829–1838, 1994

    PubMed  Google Scholar 

  56. Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ: Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17: 2235–2249, 1998

    Article  PubMed  Google Scholar 

  57. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A: p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9: 1165–1172, 1989

    PubMed  Google Scholar 

  58. Pegram MD, Konecny GE, O’Callaghan C, Malgorzata B, Pietras R, Slamon DJ: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96: 739–749, 2004

    PubMed  Google Scholar 

  59. Yarden Y: The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 37: S3–S8, 2001

    Article  Google Scholar 

  60. Klapper LN, Waterman H, Sela M, Yarden Y: Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 60: 3384–3388, 2000

    PubMed  Google Scholar 

  61. Mosesson Y, Shtiegman K, Katz M, Zwang Y, Vereb G, Szollosi J, Yarden Y: Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. J Biol Chem 278: 21323–21326, 2003

    Article  PubMed  Google Scholar 

  62. Klapper LN, Kirschbaum MH, Sela M, Yarden Y: Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. In: Klein G, Woude V (eds) Adv Cancer Research. Academic Press, London, 2000, pp. 25–79

    Google Scholar 

  63. Austin CD, De Maziere AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, Klumperman J, Scheller RH: Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 15: 5268–5282, 2004

    Article  PubMed  Google Scholar 

  64. Epstein M, Ayala R, Tchekmedyian N, Borgstrom P, Pegram M, Slamon D: HER2-overexpressing human breast cancer xenografts exhibit increased angiogenic potential mediated by vascular endothelial growth factor (VEGF) [abstract]. Breast Cancer Res Treat 76(Suppl 1): S143, 2002 (Abstract 570)

  65. Konecny GE, Meng YG, Untch M, Wang H-J, Bauerfeind I, Epstein M, Stieber P, Vernes J-M, Gutierrez J, Hong K, Beryt M, Hepp H, Slamon DJ, Pegram MD: Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 10: 1706–1716, 2004

    PubMed  Google Scholar 

  66. Clynes RA, Towers TL, Presta LG, Ravetch JV: Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nature Med 6: 443–446, 2000

    Article  PubMed  Google Scholar 

  67. Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ: Monoclonal antibody to HER-2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59: 1347–1355, 1999

    PubMed  Google Scholar 

  68. Shak S: Overview of the trastuzumab (Herceptin) anti-HER2 monclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol 26(4 Suppl 12): 71–77, 1999

    PubMed  Google Scholar 

  69. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen RP, Twaddell T, Henderson IC, Norton L: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14: 737–744, 1996

    PubMed  Google Scholar 

  70. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16: 2659–2671, 1998

    PubMed  Google Scholar 

  71. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639–2648, 1999

    PubMed  Google Scholar 

  72. Osoba D, Slamon DJ, Burchmore M, Murphy M: Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 20: 3106–3113, 2002

    Article  PubMed  Google Scholar 

  73. Mass RD, Press M, Anderson S, Slamon D: Improved survival benefit from Herceptin (trastuzumab) and chemotherapy in patients selected by fluorescence in situ hybridization [abstract]. Breast Cancer Res and Treat 69: 213, 2001 (Abstract 18)

  74. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719–726, 2002

    Article  PubMed  Google Scholar 

  75. Gelmon K, Arnold A, Verma S, Ayoub J, Hemmings F, Leyland-Jones B: Pharmacokinetics (PK) and safety of trastuzumab (Herceptin) when administered every three weeks to women with metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 20: 69a, 2001 (Abstract 271)

  76. Cook-Bruns N: Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 61(Suppl 2): 58–66, 2001

    Article  PubMed  Google Scholar 

  77. Roche: Herceptin product monograph. Gardiner-Caldwell Communications Ltd., Macclesfield, Cheshire, UK, 2001

  78. Crone SA, Zhao Y-Y, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, Ross Jr J, Chien KR, Lee K-F: ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Med 8: 459–465, 2002

    Article  PubMed  Google Scholar 

  79. Chien KR: Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity. Semin Oncol 27: 9–14, discussion 92–100, 2000

    Google Scholar 

  80. Sheng Z, Pennica D, Wood WI, Chien KR: Cardiotrophin-I displays early expression in the murine heart tube and promotes cardiac myocyte survival. Development 122: 419–428, 1996

    PubMed  Google Scholar 

  81. Sheng Z, Knowlton K, Chen J, Hoshijima M, Brown JH, Chien KR: Cardiotrophin I (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. Divergence from downstream CT-1 signals for myocardial cell hypertrophy. J Biol Chem 272: 5783–5791, 1997

    Article  PubMed  Google Scholar 

  82. Hirota H, Chen J, Betz UA, Rajewsky K, Gu Y, Ross J Jr, Muller W, Chien KR: Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 97: 189–198, 1999

    Article  PubMed  Google Scholar 

  83. Grant SL, Hammacher A, Douglas AM, Goss GA, Mansfield RK, Heath JK, Begley CG: An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells. Oncogene 21: 460–474, 2002

    Article  PubMed  Google Scholar 

  84. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart S, Keefe D: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20: 1215–1221, 2002

    Article  PubMed  Google Scholar 

  85. Geyer Jr CE, Bryant J, Romond E, Tan-Chiu E, Ewer M, Keefe D, Shannon R, Yothers G, Brown A, Fehrenbacher L, Vogel V, Seay TE, Flynn PJ, Wolmark N: Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of adriamycin and cyclophosphamide (AC) followed by taxol to that of AC followed by taxol plus herceptin in patients (pts) with operable, node-positive (N+), HER-2 overexpressing breast cancer (HER2+ BC) [abstract]. Breast Cancer Res Treat 2003 (Abstract 23)

  86. Keefe DL: Trastuzumab-associated cardiotoxicity. Cancer 95: 1592–1600, 2002

    Article  PubMed  Google Scholar 

  87. McKeage K, Perry CM: Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 62: 209–243, 2002

    PubMed  Google Scholar 

  88. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP: Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19: 2722–2730, 2001

    PubMed  Google Scholar 

  89. Jahanzeb M, Mortimer JE, Yunus F, Irwin DH, Speyer J, Koletsky AJ, Klein P, Sabir T, Kronish L: Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2+ metastatic breast cancer. The Oncologist 7: 410–417, 2002

    Article  PubMed  Google Scholar 

  90. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN: Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20: 1800–1808, 2002

    Article  PubMed  Google Scholar 

  91. Uber KA, Nicholson BP, Thor AD, Merkel DE, Goldstein LJ, Gradishar WJ, Sledge GW: A Phase II trial of weekly docetaxel (D) and herceptin (H) as first- or second-line treatment in HER2 over-expressing metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 20: 50b, 2001 (Abstract 1949)

  92. Burris HA III: Docetaxel (Taxotere) plus Trastuzumab (Herceptin) in breast cancer. Semin Oncol 28(1 Suppl 3): 38–44, 2001

    Article  Google Scholar 

  93. Theodoulou M, Campos SM, Batist G, Winer E, Norton L, Hudis C, Welles L: TLC D99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis [abstract]. Proc Am Soc Clin Oncol 21: 55a, 2002 (Abstract 216)

  94. Untch M, Schaller G, Jaenicke F, Jonat W, Langer B, Lueck HJ: Cardiac safety of Herceptin in combination with epirubicin plus cyclophosphamide: interim results of a phase II study in patients with metastatic breast cancer [abstract]. Eur J Cancer 27: 6, 2001 (Abstract 724)

  95. O’Shaughnessy JA, Vukelja S, Marsland T, Kimmel G, Ratnam S, Pippen J: Gemcitabine and trastuzumab for HER-2 positive metastatic breast cancer: preliminary results of a phase II study [abstract]. Breast Cancer Res Treat 69: 302, 2001 (Abstract 523)

    Google Scholar 

  96. Miller KD, Sisk J, Ansari R, Gize G, Nattam S, Pennington K, Monaco F, Sledge GW Jr.: Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology 15(2 Suppl 3): 38–40, 2001

    PubMed  Google Scholar 

  97. Bangemann N, Kuhle A, Ebert A, Buhler H, Schaller G: Capecitabine combined with trastuzumab in the therapy of intensively pretreated HER2-overexpressing metastatic breast cancer (MBC) [abstract]. Ann Oncol 11(Suppl 4): 143, 2000 (Abstract 653)

    Google Scholar 

  98. Pegram MD, Pienkowski T, Northfelt DW, Eiermann W, Patel R, Fumoleau P, Quan E, Crown J, Toppmeyer D, Smylie M, Riva A, Blitz S, Press MF, Reese D, Lindsay M-A, Slamon DJ: Results of two open-label, multicenter phase II studies of docetaxel, platinum salts and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 96: 759–769, 2004

    PubMed  Google Scholar 

  99. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju RN, Cobleigh M, Albain K, Slamon DJ: Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival [abstract]. Proc Am Soc Clin Oncol 23: 20, 2004 (Abstract 573)

  100. Brufsky AM, Cleary D, Fuchs C, Lebish J, Baar J, Evans T, Lembersky B, Belani CP: First-line chemotherapy for metastatic breast cancer (MBC) with docetaxel (T), carboplatin (C), and trastuzumab (H) (TCH): A phase II trial [abstract]. Proc Am Soc Clin Oncol 22: 18, 2003 (Abstract 71)

  101. Rowland KM, Suman VJ, Ingle NJ, Loprinzi CL, Flynn PJ, Krook JE, Salim M, Mailliard JA, Kardinal CG, Perez EA: NCCTG 98-32-52: Randomized phase II trial of weekly versus every 3-week administration of paclitaxel, carboplatin and trastuzumab in women with HER2 positive metastatic breast cancer (MBC) [abstract]. Proc Am Soc Clin Oncol 22: 8, 2003 (Abstract 31)

  102. Wright C, Nicholson S, Angus B, Sainsbury JR, Farndon J, Cairns J, Harris AL, Horne CH: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65: 118–121, 1992

    PubMed  Google Scholar 

  103. Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, O’Sullivan J, Martino S, Osborne CK: HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group study. Clin Cancer Res 4: 7–12, 1998

    PubMed  Google Scholar 

  104. Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, Harvey HA, Brady C, Nalin CM, Dugan M, Carney W, Allard J: Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 20: 1467–1472, 2002

    Article  PubMed  Google Scholar 

  105. Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J: Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 16: 462–469, 1998

    PubMed  Google Scholar 

  106. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D’Antonio A, Bianco AR, De Placido S: c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14: 2702–2708, 1996

    PubMed  Google Scholar 

  107. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW: Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Brit J Cancer 79: 1220–1226, 1999

    Article  PubMed  Google Scholar 

  108. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596–2606, 2001

    PubMed  Google Scholar 

  109. Fisher B, Redmond C, Brown A, Wickerham DL, Wolmark N, Allegra J, Escher G, Lippman M, Savlov E, Wittliffet J: Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1: 227–241, 1983

    PubMed  Google Scholar 

  110. Coradini D, Oriana S, Biganzoli E, Marubini E, Borachi P, Bresciani G, Di Fronzo G, Daidone MG: Relationship between steroid receptors (as continuous variables) and response to adjuvant treatments in postmenopausal women with node-positive breast cancer. Int J Biol Markers 14: 60–67, 1999

    PubMed  Google Scholar 

  111. Harvey JM, Clark GM, Osborne CK, Alfred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474–1481, 1999

    PubMed  Google Scholar 

  112. Trinchieri G: Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 70: 83, 1998

    PubMed  Google Scholar 

  113. Colombo MP, Trinchieri G: Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13: 155–168, 2002

    Article  PubMed  Google Scholar 

  114. Robertson MJ, Cameron C, Atkins MB, Gordon MS, Lotze MT, Sherman ML, Ritz J: Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res 5: 9–16, 1999

    PubMed  Google Scholar 

  115. Parihar R, Nadella P, Jensen R, Dierksheide J, Shapiro C, Carson W: A phase I trial of Herceptin and interleukin-12 in patients with HER2-overexpressing malignancies [abstract]. Proc Am Soc Clin Oncol 20: 258a, 2001 (Abstract 1031)

  116. Repka T, Chiorean EG, Gay J, Herwig KE, Kohl VK, Yee D, Miller JS: Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. Clin Cancer Res 9: 2440–2446, 2003

    PubMed  Google Scholar 

  117. Pegram MD, Yeon C, Ku NC, Gaudreault J, Slamon DJ: Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF) [abstract]. Breast Cancer Res Treat 88: 124–125, 2004 (Abstract 3039)

    Google Scholar 

  118. Burris III HA, Storniolo AM, Overmoyer EA, Pegram MD, Jones SF, Peacock NW, Loftiss JI, Koch KM, Paul E, Beelen AP, Pandite L: A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinig (GW572016) in combination with trastuzumab [abstract]. Breast Cancer Res Treat 88: 126, 2004 (Abstract 3043)

    Google Scholar 

  119. Yardley DA, Hainsworth JD, Greco FA, Houston GA, Broome CM, Thompson DS, Erland JB, White MB, Burris III HA: Preserved chemosensitivity to weekly paclitaxel and carboplatin in HER2+ patients irrespective of responses to first-line intensified induction herceptin single agent therapy [abstract]. Proc Am Soc Clin Oncol 21: 50a, 2002 (Abstract 127)

  120. O’Shaughnessy JA: Recent advances in the treatment of metastatic breast cancer. Clin Oncol Updates 5: 1–17, 2002

    Google Scholar 

  121. Hurley J, Franco S, Velez P, Doliny P, Gomez-Fernandez C, Powell J, Lee Y: Primary therapy with Herceptin, taxotere and cisplatin in locally advanced and inflammatory breast cancer [abstract]. Proc Am Soc Clin Oncol 20: 31b, 2001 (Abstract 1871)

  122. Burstein HJ, Harris LN, Kaelin CM, Christian RL, Parker LM, Gelman R, Ellisen LW, Kuter I, Gadd MA, Kennedy PR, Borges V, Bunnell CA, Tribou L, Younger J, Smith BL, Winer EP: Preoperative Herceptin and paclitaxel for HER2 overexpressing (HER2+) stage II/III breast cancer [abstract]. Proc Am Soc Clin Oncol 20: 26a, 2001 (Abstract 100)

  123. Harris L, Burstein HJ, Gelman R, Hallor M, Smith D, Borges V, Kaelin C, Bellon J, Kuter I, Winer EP: Preoperative trastuzumab and vinorelbine (HN) is a highly active, well-tolerated regimen for HER2 3+/FISH+ stage II/III breast cancer [abstract]. Proc Am Soc Clin Oncol 22: 2003 (Abstract 86)

  124. Buzdar AU, Hunt K, Smith T, Francis D, Ewer M, Booser D, Singletary E, Buchholz T, Sahin A, Hortobagyi GN: Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P) and anthracycline-containing chemotherapy (CT): Initial results of a randomized trial in operable breast cancer (BC) with HER2 positive disease [abstract]. Proc Am Soc Clin Oncol 22: 2004 (Abstract 520)

  125. Harries M, Smith I: The development and clinical use of trastuzumab (Herceptin). Endocrine-Related Cancer 9: 75–85, 2002

    Article  PubMed  Google Scholar 

  126. Romond EH, Perez EA, Bryant J, Suman V, Geyer CE, Davidson N, Tan-Chiu E, Martino S, Swain SM, Kaufman P, Fehrenbacher L, Pisansky T, Vogel V, Kutteh LA, Yothers G, Visscher D, Brown AM, Jenkins R, Seay TE, Mamounas E, Abrams J, Wolmark N: Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer: Combined analysis of NSABP-B31/NCCTG-N9831 [virtual presentation]. ASCO 2005 Symposium http://www.asco.org

  127. Piccart-Gebhart MJ: First results of the HERA trial [virtual presentation]. ASCO 2005 Symposium http://www.asco.org

  128. Slamon DJ: HER2/neu: Target identification and target validation in pathogenesis—clinical application [virtual presentation]. ASCO 2005 Symposium http://www.asco.org

  129. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL: Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activiation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21: 6255–6263, 2002

    Article  PubMed  Google Scholar 

  130. Allen LF, Lenehan PF, Eiseman IA, Elliott WL, Fry DW: Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol 29(3 Suppl 11): 11–21, 2002

    Article  Google Scholar 

  131. Barbacci EG, Boscoe BP, Cox ED, Emerson E, Iwata K, Jani J, Kath JC, Liu Z, Miller PE, Moyer JD, Provoncha K, Pustilnik LR, Rossi AK: The biological and biochemical effects of CP-654777, a selective erbB2 kinase inhibitor, on human breast cancer cells [abstract]. Proc Am Assoc Cancer Res 43: 1002, 2002 (Abstract 4969)

Download references

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology and the Jonsson Comprehensive Cancer Center, University of California, Los Angeles

    Christina H. Yeon & Mark D. Pegram

  2. Wilshire Oncology Medical Group, Inc., 50 Bellefontaine Street Suite #304, Pasadena, CA, 91105

    Christina H. Yeon

Authors
  1. Christina H. Yeon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark D. Pegram
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christina H. Yeon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yeon, C.H., Pegram, M.D. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs 23, 391–409 (2005). https://doi.org/10.1007/s10637-005-2899-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-005-2899-8

Keywords

Search

Navigation